175 related articles for article (PubMed ID: 32841774)
21. Assessment of HER-2/neu, с-MYC and CCNE1 gene copy number variations and protein expression in endometrial carcinomas.
Buchynska LG; Brieieva OV; Iurchenko NP
Exp Oncol; 2019 Jun; 41(2):138-143. PubMed ID: 31262163
[TBL] [Abstract][Full Text] [Related]
22. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
[TBL] [Abstract][Full Text] [Related]
23. Long non‑coding RNA CASC2 inhibits progression and predicts favorable prognosis in epithelial ovarian cancer.
Xue Z; Zhu X; Teng Y
Mol Med Rep; 2018 Dec; 18(6):5173-5181. PubMed ID: 30320385
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
25. c-myc and chromosome 8 centromere studies of ovarian cancer by interphase FISH.
Wang ZR; Liu W; Smith ST; Parrish RS; Young SR
Exp Mol Pathol; 1999 Jun; 66(2):140-8. PubMed ID: 10409442
[TBL] [Abstract][Full Text] [Related]
26. Multivariate analyses of DNA index, p62c-myc, and clinicopathological status of patients with ovarian cancer.
Curling M; Stenning S; Hudson CN; Watson JV
J Clin Pathol; 1998 Jun; 51(6):455-61. PubMed ID: 9771445
[TBL] [Abstract][Full Text] [Related]
27. DNA ploidy and MYC DNA amplification in ovarian carcinomas. Correlation with p53 and bcl-2 expression, proliferative activity and prognosis.
Diebold J; Suchy B; Baretton GB; Blasenbreu S; Meier W; Schmidt M; Rabes H; Löhrs U
Virchows Arch; 1996 Nov; 429(4-5):221-7. PubMed ID: 8972757
[TBL] [Abstract][Full Text] [Related]
28. lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study.
Martini P; Paracchini L; Caratti G; Mello-Grand M; Fruscio R; Beltrame L; Calura E; Sales G; Ravaggi A; Bignotti E; Odicino FE; Sartori E; Perego P; Katsaros D; Craparotta I; Chiorino G; Cagnin S; Mannarino L; Ceppi L; Mangioni C; Ghimenti C; D'Incalci M; Marchini S; Romualdi C
Clin Cancer Res; 2017 May; 23(9):2356-2366. PubMed ID: 27827314
[No Abstract] [Full Text] [Related]
29. Overexpression of long noncoding RNA HOXB-AS3 indicates an unfavorable prognosis and promotes tumorigenesis in epithelial ovarian cancer via Wnt/β-catenin signaling pathway.
Zhuang XH; Liu Y; Li JL
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31337688
[TBL] [Abstract][Full Text] [Related]
30. Increased expression of long noncoding RNA HMMR-AS1 in epithelial ovarian cancer: an independent prognostic factor.
Chu ZP; Dai J; Jia LG; Li J; Zhang Y; Zhang ZY; Yan P
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8145-8150. PubMed ID: 30556852
[TBL] [Abstract][Full Text] [Related]
31. The gene copy number of c-MET has a significant impact on progression-free survival in Korean patients with ovarian carcinoma.
Kim WY; Shim SH; Jung HY; Dong M; Kim SN; Lee SJ
Hum Pathol; 2017 Jun; 64():98-105. PubMed ID: 28428108
[TBL] [Abstract][Full Text] [Related]
32. Circ-ITCH correlates with small tumor size, decreased FIGO stage and prolonged overall survival, and it inhibits cells proliferation while promotes cells apoptosis in epithelial ovarian cancer.
Luo L; Gao Y; Sun X
Cancer Biomark; 2018; 23(4):505-513. PubMed ID: 30347599
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of thymic stromal lymphopoietin is correlated with poor prognosis in epithelial ovarian carcinoma.
Xu L; Guo Y; Xu N; Chen L; Zhu J; Liu N; Zhang ZY
Biosci Rep; 2019 May; 39(5):. PubMed ID: 31023965
[TBL] [Abstract][Full Text] [Related]
34. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer.
Fu Y; Biglia N; Wang Z; Shen Y; Risch HA; Lu L; Canuto EM; Jia W; Katsaros D; Yu H
Gynecol Oncol; 2016 Dec; 143(3):642-649. PubMed ID: 27667152
[TBL] [Abstract][Full Text] [Related]
36. Atezolizumab and blockade of LncRNA PVT1 attenuate cisplatin resistant ovarian cancer cells progression synergistically via JAK2/STAT3/PD-L1 pathway.
Chen Y; Li F; Li D; Liu W; Zhang L
Clin Immunol; 2021 Jun; 227():108728. PubMed ID: 33878452
[TBL] [Abstract][Full Text] [Related]
37. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
38. Overexpression of lncRNA MNX1-AS1 is associated with poor clinical outcome in epithelial ovarian cancer.
Li AH; Zhang HH
Eur Rev Med Pharmacol Sci; 2017 Dec; 21(24):5618-5623. PubMed ID: 29271994
[TBL] [Abstract][Full Text] [Related]
39. High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer.
Deng Y; Liu L; Feng W; Lin Z; Ning Y; Luo X
Recent Pat Anticancer Drug Discov; 2021; 16(4):533-539. PubMed ID: 34551701
[TBL] [Abstract][Full Text] [Related]
40. Long non-coding RNA CPS1-IT1 is a positive prognostic factor and inhibits epithelial ovarian cancer tumorigenesis.
Wang YS; Ma LN; Sun JX; Liu N; Wang H
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(14):3169-3175. PubMed ID: 28770969
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
